Reni Benjamin

In a report published Wednesday, Burrill Institutional Research analyst Reni Benjamin downgraded Sarepta Therapeutics (NASDAQ: SRPT) from Market Outperform to Market Perform, and removed the $39.00 price target. In the report, Burrill Institutional Research noted, “We are downgrading our rating...

Aeterna Zentaris Inc. (NASDAQ: AEZS)(FREE stock trend analysis) is expected to derive its intrinsic value through a rich portfolio of early and mid-stage assets. According to a report released by Rodman & Renshaw, Aeterna Zentaris Inc. has stated that the firm is currently discussing the...